Table 2 Differences in clinicopathologic results among the 3 groups stratified by the location of positive lymph nodes.
|  | Group 1, N = 206 | Group 2, N = 63 | Group 3, N = 25 | P-value |
|---|---|---|---|---|
Age, years: mean (SD) | 63.3 (6.9) | 63.3 (7.4) | 64.4 (8.1) | 0.744 |
PSA, ng/ml: mean (SD) | 21.6 (36.0) | 26.9 (85.5) | 37.3 (66.5) | 0.336 |
BCR-free survival, months: mean (range) | 19.2 (0.7-77.7) | 21.6 (1.0-76.3) | 19.6 (2.6-60.0) | 0.163 |
BCR: N (%) | Â | Â | Â | 0.073 |
 No | 145 (70.4) | 35 (55.6) | 15 (60.0) |  |
 Yes | 61 (29.6) | 28 (44.4) | 10 (40.0) |  |
D’Amico risk: N (%) |  |  |  | 0.009 |
 Low risk | 29 (14.1) | 7 (11.1) | 1 (4.0) |  |
 Intermediate risk | 65 (31.6) | 17 (27.0) | 1 (4.0) |  |
 High risk | 112 (54.4) | 39 (61.9) | 23 (92.0) |  |
Biopsy GS: N (%) | Â | Â | Â | <0.001 |
 6-7 | 116 (56.5) | 25 (41.0) | 5 (20.0) |  |
 8-10 | 89 (43.4) | 36 (59.0) | 20 (80.0) |  |
Pathologic GS: N (%) | Â | Â | Â | 0.021 |
 6-7 | 113 (54.9) | 29 (46.0) | 8 (32.0) |  |
 8-10 | 93 (45.1) | 34 (54.0) | 17 (68.0) |  |
Pathologic T stage: N (%) | Â | Â | Â | 0.005 |
 T2 | 81 (39.3) | 18 (28.6) | 3 (12.0) |  |
 T3a | 48 (23.3) | 22 (34.9) | 6 (24.0) |  |
 T3b | 59 (28.6) | 19 (30.2) | 10 (40.0) |  |
 T4 | 18 (8.7) | 4 (6.3) | 6 (24.0) |  |
Margin status: N (%) | Â | Â | Â | 0.043 |
 Negative | 69 (33.5) | 37 (58.7) | 9 (36.0) |  |
 Positive | 137 (66.5) | 26 (41.3) | 16 (64.0) |  |
Adjuvant therapy: N (%) | Â | Â | Â | 0.012 |
 No | 165 (80.1) | 42 (66.7) | 16 (64.0) |  |
 Yes | 41 (19.9) | 21 (33.3) | 9 (36.0) |  |